We'll still need healthcare products and services in the future, whether we're talking about 10 or 100 years from now. The ...

Dogecoin (DOGE 0.70%) remains a fundamentals-free asset, yet its price keeps reviving whenever the macroeconomic tides shift. Ignoring the patterns that drive its price risks miss ...

Investors with some cash to deploy should consider buying some shares, and I've got five stocks that look like excellent long ...

At 114 times sales, Palantir's stock is mind-bogglingly expensive. Most software companies trade in the range of 10 to 20 ...

In his "The Power of 21" presentation, Saylor specifically points out the new pro-crypto approach of the Trump administration, which has led to new euphoria around Bitcoin as an asset class. The White ...

This fund shines bright on the cost front. With an expense ratio of 0.03%, Vanguard would take just $0.30 in annual fees for ...

The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per ...